Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Edoardo Mannucci, Stefano Giannini & Ilaria Dicembrini. (2015) Cardiovascular effects of basal insulins. Drug, Healthcare and Patient Safety 7, pages 113-120.
Read now
Read now
Articles from other publishers (12)
Esra Ayan & Hasan DeMirci. (2023) A Brief Atlas of Insulin. Current Diabetes Reviews 19:6.
Crossref
Crossref
Gergely Á. Visolyi, Beatrix A. Domján, Márk M. Svébis, Anna Péterfi, Barbara D. Lovász, Szilvia Mészáros, Viktor J. Horváth & Ádám G. Tabák. (2023) Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis. Canadian Journal of Diabetes 47:4, pages 368-377.
Crossref
Crossref
Edoardo Mannucci, Chiara Caiulo, Lara Naletto, Giuseppe Madama & Matteo Monami. (2021) Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine 74:3, pages 508-517.
Crossref
Crossref
Alice Y. Y. Cheng, Jencia Wong, Nick Freemantle, Shamasunder H. Acharya & Elif Ekinci. (2020) The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review. Diabetes Therapy 11:11, pages 2555-2593.
Crossref
Crossref
C. Lualdi, A. Silverii, I. Dicembrini, L. Pala, M. Monami & E. Mannucci. (2018) Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study. Journal of Endocrinological Investigation 42:3, pages 319-326.
Crossref
Crossref
Xiao-Wen Zhang, Xin-Lin Zhang, Biao Xu & Li-Na Kang. (2018) Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetologica 55:5, pages 429-441.
Crossref
Crossref
M. Rodacki, R.M. Carvalho & L. Zajdenverg. (2017) The potential effect of ultra-long insulin degludec on glycemic variability. Diabetes Research and Clinical Practice 133, pages 92-103.
Crossref
Crossref
Akizuki Morikawa, Yuko Morikawa, Masahiro Nomura, Jun Watanabe, Hiroya Kitsunai & Masakazu Haneda. (2015) Has the safety of diabetes therapy improved? Lessons from an analysis of diabetic medication-induced severe hypoglycemic cases in an emergency department from 2005 to 2013. Diabetology International 7:3, pages 274-280.
Crossref
Crossref
Anna Tokajuk, Edyta Krzy?anowska-Grycel, Adrian Tokajuk, S?awomir Grycel, Anna Sadowska & Halina Car. (2015) Antidiabetic drugs and risk of cancer. Pharmacological Reports 67:6, pages 1240-1250.
Crossref
Crossref
Lang Wu, Jingjing Zhu, Larry J. Prokop & Mohammad Hassan Murad. (2015) Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Scientific Reports 5:1.
Crossref
Crossref
K. Dżygało, D. Golicki, A. Kowalska & A. Szypowska. (2014) The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials. Acta Diabetologica 52:2, pages 231-238.
Crossref
Crossref
Cheow Peng Ooi, Tzer Hwu Ting & Seng Cheong Loke. (2014) Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Crossref